Table 1.
Vaccines used in COV-BOOST trial
| Mechanism of action | Administration | |
|---|---|---|
| ChAdOx-nCov19 (ChAd; AZD1222, AstraZeneca) | Replication-deficient chimpanzee adenovirus vectored vaccine, expressing the SARS-CoV-2 spike surface glycoprotein | 5 × 1010 viral particles per 0·5 mL via intramuscular injection |
| NVX-CoV2373 (NVX; Novavax) | Nanoparticle vaccine containing purified spike glycoprotein | 5 μg with Matrix-M1 50 μg adjuvant in 0·5 mL via intramuscular injection |
| NVX-CoV2373 (NVX half; Novavax) | Nanoparticle vaccine containing purified spike glycoprotein | 2·5 μg with Matrix-M1 25 μg adjuvant in 0·25 mL via intramuscular injection |
| BNT162b2 (BNT; Pfizer–BioNTech) | mRNA vaccine encoding SARS-CoV-2 spike glycoprotein | 30 μg in 0·3 mL via intramuscular injection |
| BNT162b2 (BNT half; Pfizer–BioNTech) | mRNA vaccine encoding SARS-CoV-2 spike glycoprotein | 15 μg in 0·15 mL via intramuscular injection |
| VLA2001 (VLA; Valneva) | Whole, inactivated SARS-CoV-2 virus | 33 antigen units with 1 mg CpG adjuvant in 0·5 mL via intramuscular injection |
| VLA2001 (VLA half; Valneva) | Whole, inactivated SARS-CoV-2 virus | 16·5 antigen units with 0·5 mg CpG adjuvant in 0·25 mL via intramuscular injection |
| Ad26.COV2.S (Ad26; Janssen) | Replication-deficient adenovirus vector vaccine constructed to encode a full-length spike protein | 5 × 1010 viral particles per mL in 0·5 mL via intramuscular injection |
| mRNA1273 (m1273; Moderna) | mRNA vaccine encoding SARS-CoV-2 spike glycoprotein | 100 μg administered via 0·5 mL via intramuscular injection |
| CVnCoV (CVn; Curevac), withdrawn from further clinical development October, 202122 | mRNA vaccine encoding SARS-CoV-2 spike glycoprotein | 12 μg administered via 0·6 mL via intramuscular injection |
| MenACWY (Pfizer) control | Quadrivalent meningococcal conjugate vaccine | 0·5 mL via intramuscular injection |